On 8 Oct 2026, LONGSYS (09976.HK) said H shares joined the Stock Connect (Shanghai/Shenzhen-Hong Kong) eligible list from 8 Oct, widening its base.
On 8 Oct 2026, SUNSHINE PHARMA (06887.HK) won NMPA approval for its insulin degludec/aspart injection, taking its approved insulin range in China to 7.
On 8 Oct 2026, CHANGHONG JH (03991.HK) declared an interim dividend of HKD 0.06 per share for the six months to 30 June, payable on 18 Dec; ex-date 30 Nov.
On 8 October 2026, SSY GROUP (02005.HK) said it won NMPA production approval for nimodipine oral solution (10ml:60mg) in China, a Category 3 chemical drug.
On October 8, 2026, Hong Kong stocks fell broadly, with the HSTECH down 2.89% to a new low since September 2024. MINIMAX-W slumped 13.74%; BABA-W eased 1.04%.
A Roundup of "First Stocks" in Hong Kong IPOs (September 2026)&......
On 8 October 2026, DA SEN HLDGS (01580.HK) terminated a placing of up to 219,120,000 new shares at HKD 0.241 each, citing unstable market conditions.
On 7 October 2026, LDROBOT (01236.HK) agreed to buy German garden machinery maker SABO-Maschinenfabrik for up to EUR6 million, a discloseable transaction.
On 7 Oct 2026, SA SA INT'L (00178.HK) said HK and Macau offline sales rose over 60% year-on-year in the 1-7 October holiday, with same-store sales up over 50%.
On 7 October 2026, KFM KINGDOM (03816.HK) announced that Quam Capital Limited has been appointed as the Independent Financial Adviser.
On 6 Oct 2026, MEDIALINK GROUP (02230.HK) said Ma Zhengfeng resigned as executive director and company secretary; Yip Ting Sum was appointed in his place.
On 6 Oct 2026, CNE TECH CORP (00611.HK) cut the consideration for its Ningxia target acquisition by 10.5% to RMB71.93m on policy, financing and site issues.
On 6 October 2026, MOISELLE INT'L (00130.HK) announced that it received a conversion notice on 5 October 2026 to exercise the conversion right attached to convertible bonds with an aggregate principal amount of HKD 15 million at a conversion price of HKD 0.3 per share, and allotted and issued 50,000,000 conversion shares on 6 October 2026.
On 5 October 2026, WYNN MACAU (01128.HK) announced that it granted awards over a total of 317,938 shares to 315 employees of the Group under its Employee Share Ownership Plan adopted on 25 May 2023, representing approximately 0.01% of its issued share capital as at the date of the announcement, at a nil purchase price.
On 5 October 2026, SIHUAN PHARM (00460.HK) announced that five new specifications of the injectable sodium hyaluronate complex solution (product name: Dongyan), developed by its subsidiary Meiyan Space, have been approved for marketing by China's National Medical Products Administration, namely 0.75 mL, 1.25 mL, 1.75 mL, 2.25 mL and 2.75 mL per vial.
On 5 October 2026, MAOYAN ENT (01896.HK) announced that its board approved a plan to exercise the share buy-back mandate granted by shareholders at the AGM held on 23 June 2026, under which the Company may spend up to approximately HKD 250 million to repurchase shares on the open market from the date of the announcement until the date of its next AGM in 2027.
